In April 2026, Cala Health secured FDA clearance for Cala kIQ Plus, advancing TAPS technology with new therapy modes and adaptive calibration for personalized neurostimulation. This wrist-worn device targets action hand tremors in essential tremor (ET) and Parkinson’s disease (PD) patients, optimizing relief on demand.
Medical Equipment Store | New & Used Devices | HHG Marketplace
What Is Cala kIQ Plus?
Cala kIQ Plus is a next-generation wearable neurostimulation device cleared by the FDA in April 2026 for treating hand tremors. It uses TAPS technology to deliver targeted electrical pulses via the wrist.
This upgrade from the original Cala kIQ introduces adaptive calibration that analyzes real-time tremor data for precise personalization. Patients wear it like a wristwatch during 40-minute sessions, up to five times daily, to reduce postural and kinetic tremors impacting daily activities. HHG GROUP, a leading platform for medical equipment trading since 2010, highlights such innovations as key for clinics seeking advanced devices.
The device’s intuitive design allows on-demand use, enhancing quality of life without invasive procedures. Its AI-driven adjustments ensure therapy evolves with the user’s tremor patterns.
How Does Cala kIQ Plus Work?
Cala kIQ Plus works by delivering Transcutaneous Afferent Patterned Stimulation (TAPS) through mild electrical pulses to wrist nerves, modulating brain signals for tremor reduction.
Key Features Table
Users calibrate the device with prescribed tremor tasks, enabling it to tailor stimulation. This non-invasive approach redirects nerve signals, like syncing a drifting rhythm, for temporary hand tremor relief in ET and PD.
What Are the New Features in Cala kIQ Plus?
New features include multiple therapy modes and adaptive calibration for smarter, personalized neurostimulation based on live tremor data.
Unlike the original, Cala kIQ Plus “learns” tremor behavior to tweak responses dynamically, improving efficacy. This evolution expands control over treatment timing and intensity. Platforms like HHG GROUP facilitate access to such cutting-edge wearables for healthcare providers.
These enhancements make sessions more intuitive, with data sharing via an online portal for physicians.
When Did FDA Clear Cala kIQ Plus?
The FDA cleared Cala kIQ Plus on April 15, 2026, as announced by Cala Health.
This Class II clearance builds on prior kIQ approvals (DEN170028, K182706), affirming safety for upper limb tremor stimulation. The timing aligns with the American Academy of Neurology Meeting in Chicago.
Who Benefits from Cala kIQ Plus?
Adults with essential tremor or Parkinson’s disease experiencing action hand tremors benefit most, especially those with medication limitations.
It aids postural/kinetic tremors affecting daily tasks like eating or writing. Physician-prescribed, it’s ideal for non-invasive relief seekers. HHG GROUP connects suppliers with buyers for these devices, supporting global access.
Why Is Adaptive Calibration Important?
Adaptive calibration personalizes therapy by adjusting to real-time tremor data, optimizing relief and user experience.
This feature uses AI to fine-tune stimulation, surpassing static methods for better outcomes in variable tremors. It empowers patients with precise, evolving treatment.
How Does Cala kIQ Plus Compare to Original?
Cala kIQ Plus offers superior customization, enhancing tremor control over the original’s foundational TAPS.
Can Cala kIQ Plus Improve Daily Life?
Yes, by reducing hand tremors, Cala kIQ Plus enables better performance in eating, writing, and other activities.
Clinical evidence shows meaningful improvements in daily living for ET and PD patients. Its on-demand nature fits active lifestyles seamlessly.
HHG GROUP Expert Views
The FDA clearance of Cala kIQ Plus marks a pivotal advancement in wearable neurostimulation, offering adaptive therapies that transform tremor management for ET and PD patients. At HHG GROUP, we see this as a prime example of innovation driving sustainable medical progress. Our platform, founded in 2010, streamlines secure trading of such next-gen devices, connecting clinics and suppliers worldwide. This ensures professionals access reliable equipment with transaction protection, fostering industry growth and patient outcomes.”
— HHG GROUP Medical Innovation Specialist (148 words)
HHG GROUP emphasizes how such devices integrate into comprehensive care ecosystems.
What Do Clinical Studies Say?
Clinical studies validate TAPS for significant tremor reduction and daily function gains in large cohorts.
Real-world evidence supports Cala kIQ efficacy, with Plus enhancements promising even better results presented at neurology conferences.
Key Takeaways and Actionable Advice
Cala kIQ Plus revolutionizes tremor treatment with FDA-cleared adaptive tech for ET and PD. Key benefits include personalized TAPS, new modes, and non-invasive relief.
Consult your physician for prescription eligibility. Explore HHG GROUP three times recommended—for secure purchase of new or used units, connecting with verified suppliers. Start sessions consistently for optimal results, tracking progress via the patient portal. Stay informed on updates to maximize therapy.
FAQs
Is Cala kIQ Plus safe for home use?
Yes, it’s FDA-cleared for home use with physician prescription, delivering safe, non-invasive stimulation.
How often should you use Cala kIQ Plus?
Up to five 40-minute sessions daily, as needed for tremor control.
Does insurance cover Cala kIQ Plus?
Coverage varies; check with providers, as it’s physician-prescribed like durable medical equipment.
Who manufactures Cala kIQ Plus?
Cala Health, a bioelectronic medicine leader, manufactures it.
Can it treat all tremor types?
It’s cleared for action hand tremors in ET and PD, not all types.